Evidence map›Paper›PMID 29196616›Full record

ArticleScientific reports2017

17β-Estradiol sensitizes ovarian surface epithelium to transformation by suppressing Disabled-2 expression.

Nhung H Vuong, Omar Salah Salah, Barbara C Vanderhyden

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. A narrative review ofFrontiers in oncology · 2026
    Review
  2. Review
  3. Article
  4. Disabled-2 (International journal of molecular sciences · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Nhung H VuongDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada.
Omar Salah SalahCancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Barbara C VanderhydenDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada. bvanderhyden@ohri.ca.
University of Ottawa · CAOttawa Hospital · CA

Funding

CIHR
6 · The paper itself

Abstract

Estrogen replacement therapy increases the risk of human ovarian cancer and exogenous estradiol accelerates the onset of ovarian cancer in mouse models. This study uses primary cultures of mouse ovarian surface epithelium (OSE) to demonstrate that one possible mechanism by which estrogen accelerates the initiation of ovarian cancer is by up-regulation of microRNA-378 via the ESR1 pathway to result in the down-regulation of a tumour suppressor called Disabled-2 (Dab2). Estrogen suppression of Dab2 was reproducible in vivo and across many cell types including mouse oviductal epithelium and primary cultures of human ovarian cancer cells. Suppression of Dab2 resulted in increased proliferation, loss of contact inhibition, morphological dysplasia, and resistance to oncogene-induced senescence - all factors that can sensitize OSE to transformation. Given that DAB2 is highly expressed in healthy human OSE and is absent in the majority of ovarian tumours, this study has taken the first steps to provide a mechanistic explanation for how estrogen therapy may play a role in the initiation of ovarian cancer.

Indexed as

Cell Transformation, NeoplasticAdaptor Proteins, Signal TransducingAdaptor Proteins, Vesicular TransportAnimalsApoptosis Regulatory ProteinsCarcinoma, Ovarian EpithelialEpithelial CellsEpitheliumEstradiolFemaleHumansMiceMice, KnockoutOvarian NeoplasmsOvaryTumor Suppressor ProteinsAdaptor Proteins, Signal TransducingAdaptor Proteins, Vesicular TransportApoptosis Regulatory ProteinsDab2 protein, mouseEstradiolTumor Suppressor Proteins

Identifiers

PMID29196616
PMCPMC5711839
OpenAlexW2770845572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.